$190.90
−3.07%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$196.75
From 52W high−13.68%
Volume5.77M
Market cap$40.92B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$196.75
From 52W high
−13.68%
Volume
5.77M
Market cap
$40.92B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.2x
P/E (TTM)
—
RSI (14)
34.4
MomentumView details →
1D Return
−3.07%
YTD Return
+137.53%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company went public in February 2020 and focuses specifically on developing novel therapies to treat RAS-addicted cancers. RAS proteins are among the most frequently mutated oncogenes in human cancers, found in approximately 30% of all cancers and up to 95% in certain cancer types like pancreatic cancer. Revolution Medicines has built a comprehensive pipeline of RAS pathway inhibitors and is currently advancing multiple drug candidates through clinical trials, with its lead program entering Phase 3 pivotal trials.
Similar companies
Latest newsMore news →
The U.S. FDA granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma.6d agoThe FDA approved a pill from Revolution Medicines to treat late-stage prostate cancer.15d agoRevolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.18d ago